Using crystal dPCR and the naica® system (Stilla Technologies), Ntzifa et al. detected EGFR mutations in ctDNA and paired CTCs in patients with NSCLC treated with osimertinib at two-time points, before treatment and at the progression of the disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.